Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancer
Abstract
Background: Infection poses a serious risk in children and adolescents with cancer, often leading to severe morbidity and occasionally, death. Inconsistent management of fever with neutropenia (FN) may affect clinical outcomes. Despite the frequent occurrence of this complication during cancer treatment, no South African (SA) clinical practice guideline (CPG) has been developed to support clinicians in its management.
Objective: To develop an evidence-based CPG providing recommendations for diagnosis, prognosis and management of children and adolescents with FN undergoing cancer treatment in SA.
Method: We developed an evidence-based CPG for managing this condition, tailored to the unique and diverse healthcare system in which children and adolescents with cancer are treated in SA. We established a working group comprising representatives from the clinical care pathway for SA children and adolescents with cancer. We then employed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to formulate the CPG recommendations.
Conclusion: We present two definitions and 29 recommendations for managing children and adolescents with FN. The CPG development process has yielded recommendations similar to those of other FN CPGs; however, they reflect the unique context of SA, and guide elements such as tuberculosis evaluation, focusing on essential factors including availability, accuracy, affordability and diagnostic capacity. Furthermore, the…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.